Good sourcing, but language and statistical problems were prominent shortcomings in this story. Didn’t grade as well as the stories by the LA Times blog or by Reuters Health.
An incomplete and overly optimistic story about a treatment that hasn’t advanced beyond a test tube.
Excellent job on a story that received very little mainstream news media attention.
Better in some respects than the competing HealthDay coverage, but worse in others. Neither story got at the heart of why this study is important.
This story attempted to address some complicated nutrition science, but didn’t quite measure up. TIME‘s report was similar.
This was a superficial report that passed along the main findings of a study, but not much else.
After all of the research about lumpectomy & radiation versus mastectomy, what made this study new and significant? This story should have done a better job of explaining what made this a “more real-world study.”
A 275-word story that apparently came directly from a drug company news release. It leaves the reader with no new and meaningful information about the drug or disorder it targets.
A business story that is just as meaningful to patients and their family members as it is to investors.
In fewer than 500 words, this story managed to satisfactorily address 7 of our 10 criteria.
HealthDay reports on a paper published in JAMA Internal Medicine: “The costly form of radiation therapy that has become the...
A paper by New Zealand researchers published in the journal, Acta Psychiatrica Scandinavica (subscription required for full text access*), summarizes...
The following is a guest post by Harold DeMonaco, MS, one of our expert reviewers on HealthNewsReview.org, and a frequent...
We will not display your name or e-mail address on the site, nor will we share youre-mail address with any third parties.
For site updates and news from Gary, find us on Twitter:
HealthNewsReview: @HealthNewsRevu
Gary Schwitzer: @garyschwitzer
Copyright © 2013 Health News Review
